Soothing the liver and activating blood circulation for the treatment of chronic prostatitis: A systematic review and meta-analysis.

BACKGROUND

Chronic prostatitis (CP) is a commonly encountered condition within the male urinary system in clinical practice. Studies have shown that the prevalence of CP in China has risen to between 6.0% and 32.9%, with a continuing upward trend. While the method of soothing the liver and activating blood circulation (SLABC) is widely employed in traditional Chinese medicine for treating CP, a thorough analysis of its efficacy is currently lacking. This meta-analysis aims to evaluate the effectiveness and efficiency of SLABC.

METHODS

We conducted a search across 8 electronic databases, which included CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library, from their inception until October 1, 2023. The primary common outcomes assessed comprised the total effective rate, NIH-CPIS score, and traditional Chinese medicine syndrome score. Two researchers utilized Endnote 20 software for the screening of literature and the extraction of information. The Cochrane rob2.0 collaboration tool was used to evaluate the risk of bias in the trials, while data analysis was carried out using RevMan 5.3 and STATA 15 software.

RESULTS

A total of 22 randomized controlled trials involving 2470 participants were included. The results of the meta-analysis showed that SLABC combined with traditional Western medicine significantly improved the NIH-CPSI score compared with traditional Western medicine alone (mean difference [MD] = -5.23; 95% confidence interval [CI] = -7.30 to -3.15; P < .00001), and its total effective rate was comparable to that of traditional Western medicine (relative risk = 1.09; 95% CI = 0.97-1.23; P = .16). In addition, as a single treatment, SLABC was superior to traditional Western medicine in improving the NIH-CPSI score (MD = -3.67; 95% CI = -5.22 to -2.12; P < .00001), and its effective rate was comparable to that of traditional Western medicine (relative risk = 1.06; 95% CI = 0.92-1.23; P = .40). Furthermore, this approach was more effective than conventional Western medicine in relieving TCM-related symptoms (MD = -0.64; 95% CI = -0.72 to -0.57; P < .00001).

CONCLUSION

The research highlights the effectiveness of SLABC in the treatment of CP. Given the scarcity and subpar quality of pertinent articles, there is a need for more extensive and reliable randomized clinical trials to better evaluate the clinical advantages and long-term efficacy of this therapy for CP.